Treatment of irritable bowel syndrome: Sex and gender specific aspects

Handbook of Experimental Pharmacology

Volumn 214, Issue , 2012, Pages 473-497

  Voß, Ulrike ^a   Lewerenz, Anne ^b   Nieber, Karen ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b NONE   (Germany)

Author keywords

Antidepressants; Gender; Hormones; Irritabel bowel syndrom; Laxatives; Probiotics; Prostaglandins; Serotonin

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIDIARRHEAL AGENT; BENZOFURAN DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; LAXATIVE; PROBIOTIC AGENT; PRUCALOPRIDE; SEX HORMONE;

FEMALE; HUMAN; IRRITABLE COLON; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SEXUAL DEVELOPMENT;

ANTIDEPRESSIVE AGENTS; ANTIDIARRHEALS; BENZOFURANS; FEMALE; GONADAL STEROID HORMONES; HUMANS; IRRITABLE BOWEL SYNDROME; LAXATIVES; MALE; PARASYMPATHOLYTICS; PROBIOTICS; SEX CHARACTERISTICS;

EID: 84868328545     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-30726-3_21     Document Type: Article

References (116)

1. Adeyemo MA, Chang L (2008) New treatments for irritable bowel syndrome in women. Womens Health 4:605-623. doi:10.2217/17455057.4.6.605
2. Adeyemo MA, Spiegel BMR, Chang L (2010) Meta-analysis: do irritable bowel syndrome symptoms vary between men and women? Aliment Pharmacol Ther 32:738-755. doi:10.1111/j.1365-2036.2010.04409.x
3. Ahlawat SK, Cuddihy MT, Locke GR 3rd (2006) Gender-related differences in dyspepsia: a qualitative systematic review. Gend Med 3:31-42. doi:10.1016/S1550-8579(06)80192-0
4. American College of Gastroenterology Functional Gastrointestinal Disorders Task Force (2002) Evidence-based position statement on the management of irritable bowel syndrome in North America. Am J Gastroenterol 97(suppl):S1-S5
5. Ashburn TT, Gupta MS (2006) The IBS market. Nat Rev Drug Discov 55:99-100. doi:10.1038/nrd1961
6. Balsari A, Ceccarelli A, Dubini F, Fesce E, Poli G (1982) The fecal microbial population in irritable bowel syndrome. Microbiologica 5:185-94
7. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM, Grady EF, Bunnett NW, Collins SM, Corinaldesi R (2004) Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 126:693-702. doi:10.1053/j.gastro.2003.11.055
8. Bausserman M, Michail S (2005) The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J Pediatr 147:197-201. doi:10.1016/j.jpeds.2005.05.015
9. Bharucha AE, Linden DR (2010) Linaclotide - a secretagogue and antihyperalgesic agent - what next? Neurogastroenterol Motil 22:227-231. doi:10.1111/j.1365-2982.2009.01465
10. Bijkerk J, De Wit NJ, Muris JWM, Whorwell PJ, Knottnerus JA, Hoes AW (2009) Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. Br Med J 339:b3154-3163. doi:10.1136/bmj.b3154
11. Blanchard EB, Scharff L, Schwarz SP, Suls JM, Barlow DH (1990) The role of anxiety and depression in the irritable bowel syndrome. Behav Res Ther 28:401-405. doi:10.1016/0005-7967(90)90159-G
12. Blewett A, Allison M, Calcraft B, Moore R, Jenkins P, Sullivan G (1996) Psychiatric disorder and outcome in irritable bowel syndrome. Psychosomatics 37:155-160
13. Borum ML (1998) Gastrointestinal diseases in women. Med Clin North Am 82:21-50. doi:10.1016/S0025-7125(05)70593-9
14. Brandt LJ, Bjorkman D, Fennerty MB, Locke GR, Olden K, Peterson W, Quigley E, Schoenfeld P, Schuster M, Talley N (2002) Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 97(suppl):S7-S26
15. Brown PM, Drossman DA, Wood AJJ, Cline GA, Frazier KS, Jackson JI, Bronner J, Freiman J, Zambrowicz B, Sands A, Gershon MD (2011) The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome. Gastroenterology 141:507-516. doi:10.1053/j.gastro.2011.05.005
16. Cain KC, Jarrett ME, Burr RL, Rosen S, Hertig VL, Heitkemper MM (2009) Gender differences in gastrointestinal, psychological, and somatic symptoms in irritable bowel syndrome. Dig Dis Sci 54:1542-1549. doi:10.1007/s10620-008-0516- 3
17. Camilleri M (2006) Probiotics and irritable bowel syndrome: rationale, putative mechanisms, and evidence of clinical efficacy. J Clin Gastroenterol 40:264-269. doi:10.1097/00004836-200603000-00020
18. Camilleri M (2011) New treatment options for chronic constipation: mechanisms, efficacy and safety. Can J Gastroenterol. 25: Suppl B:29B-35B
19. Camilleri M (2010) New receptor targets for medical therapy in irritable bowel syndrome. Aliment Pharmacol Ther 31:35-46. doi:10.1111/j.1365-2036.2009. 04153.x
20. Camilleri M, Atanasova E, Carlson PJ, Ahmad U, Kim HJ, Viramontes BE, McKinzie S, Urrutia R (2002) Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 123:425-432. doi:10.1053/gast.2002.34780
21. 2 receptor antagonist. Br J Pharmacol 123:81-91. doi:10.1038/sj.bjp.0701587
22. Chang L (2006) From Rome to Los Angeles - The Rome III criteria for the functional GI disorders. Medscape gastroenterology. http://www.medscape.org/ viewarticle/533460. Accessed 30 May 2006
23. Chang L (2011) The role of stress on physiologic responses and clinical symptoms in irritable bowel syndrome. Gastroenterology 140:761-765.e5. doi:10.1053/j.gastro.2011.01.032
24. Chang L, Toner BB, Fukudo S, Guthrie E, Locke GR, Norton NJ, Sperber AD (2006) Gender, age, society, culture, and the patient's perspective in the functional gastrointestinal disorders. Gastroenterology 130:1435-1446. doi:10.1053/j.gastro.2005.09.071
25. Clark C, DeLegge M (2008) Irritable bowel syndrome: a practical approach. Nutr Clin Pract 23:263-267. doi:10.1177/0884533608318107
26. Cleveland M, Flavin DP, Ruben RA, Epstein RM, Clark GE (2001) New polyethylene glycol laxatives for treatment of constipation in adults: a randomized, double-blind, placebocontrolled study. South Med J 94:478-481
27. Coates MD, Mahoney CR, Linden DR, Sampson JE, Chen J, Blaszyk H, Crowell MD, Sharkey KA, Gershon MD, Mawe GM, Moses PL (2004) Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 126:1657-1664. doi:10.1053/j.gastro.2004.03.013
28. Corney RH, Stanton R (1990) Physical symptom severity, psychological and social dysfunction in a series of outpatients with irritable bowel syndrome. J Psychosom Res 34:483-491. doi:10.1016/0022-3999(90)90022-V
29. Cremon C, Gargano L, Morselli-Labate AM, Santini D, Cogliandro RF, De Giorgio R, Stanghellini V, Corinaldesi R, Barbara G (2009) Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol 104:392-400. doi:10.1038/ajg.2008.94
30. Delvaux M, Louvel D, Mamet JP, Campos-Oriola R, Frexinos J (1998) Effect of alosetron on response to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 12:849-855. doi:10.1046/j.1365-2036.1998.00375. x
31. 4 receptor agonists: similar but not the same. Neurogastroenterol Motil 20:99-112. doi:10.1111/j.1365-2982.2007.01059.x
32. Drossman DA (2006) The functional gastrointestinal disorders and the Rome III process. Gastroenterology 130:1377-1390. doi:10.1053/j.gastro.2006.03.008
33. Drossman DA, Sandler RS, McKee DC, Lovitz AJ (1982) Bowel patterns among subjects not seeking health care. Use of a questionnaire to identify a population with bowel dysfunction. Gastroenterology 83:529-534
34. Drossman DA, Toner BB, Whitehead WE, Diamant NE, Dalton CB, Duncan S, Emmott S, Proffitt V, Akman D, Frusciante K, Le T, Meyer K, Bradshaw B, Mikula K, Morris CB, Blackman CJ, Hu Y, Jia H, Li JZ, Koch GG, Bangdiwala SI (2003) Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 125:19-31. doi:10.1016/S0016-5085(03)00669-3
35. Drossman DA, Chey WD, Johanson JF, Fass R, Scott C, Panas R, Ueno R (2008) Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebo controlled studies. Aliment Pharmacol Ther 29:329-341. doi:10.1111/j.1365-2036.2008.03881.x
36. Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, Marteau P (2008) A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroenterol Clin Biol 32:147-152. doi:10.1016/j.gcb.2007.06.001
37. + exchanger 3 accumulates and is functional in recycling endosomes. J Biol Chem 273:2035-2043. doi:10.1074/jbc.273.4.2035
38. Efskind PS, Bernklev T, Vatn MH (1996) A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol 31:463-468. doi:10.3109/00365529609006766
39. Enck P, Klosterhalfen S (2005) The placebo response in functional bowel disorders: perspectives and potential mechanisms. Neurogastroenterol Motil 17:325-331. doi:10.1111/j.1365-2982.2005.00676.x
40. Fock KM, Chew CN, Tay LK, Peh LH, Chan S, Pang EP (2001) Psychiatric illness, personalities traits and the irritable bowel syndrome. Ann Acad Med Singapore 30:611-614
41. Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P (2009) Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 104:1831-1843. doi:10.1038/ajg.2009.223
42. Garakani A, Win T, Virk S, Gupta S, Kaplan D, Masand PS (2003) Comorbidity of irritable bowel syndrome in psychiatric patients: a review. Am J Ther 10:61-67. doi:10.1097/00045391-200301000-00014
43. Germann I, Hagelauer D, Kelber O, Vinson B, Laufer S, Weiser D, Heinle H (2006) Antioxidative properties of the gastrointestinal phytopharmaceutical remedy STW 5 (Iberogast). Phytomedicine 13:45-50. doi:10.1016/j.phymed.2006.03. 018
44. Guliani S, Altamura M, Maggi CA (2008) Ibodutant. Drugs Fut 33:111. doi:10.1358/dof.2008.033.02.1181381
45. Gunnarsson J, Simrén M (2009) Peripheral factors in the pathophysiology of irritable bowel syndrome. Dig Liver Dis 41:788-793. doi:10.1016/j.dld.2009.07.006
46. Heading R, Bardhan K, Hollerbach S, Lanas A, Fisher G (2006) A systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome - European perspective. Aliment Pharmacol Ther 24:207-236. doi:10.1111/j.1365-2036.2006.02937.x
47. Heitkemper M, Jarrett M (2008a) Update on irritable bowel syndrome and gender differences. Nutr Clin Pract 23:275-283. doi:10.1177/0884533608318672
48. Heitkemper M, Jarrett M (2008b) Irritable bowel syndrome: does gender matter? J Psychosom Res 64:583-587. doi:10.1016/j.jpsychores.2008.02.020
49. Heitkemper J, Jarret M, Cain KC, Burr R, Levy RJ, Feld A, Hertig V (2001) Autonomic nervous system function in women with irritable bowel syndrome. Dig Dis Sci 46:1276-1284. doi:10.1023/A:1010671514618
50. Heitkemper M, Jarret M, Bond EF, Chang L (2003) Impact of sex and gender on irritable bowel syndrome. Biol Res Nurs 5:56-65. doi:10.1177/ 1099800403005001006
51. Hellström PM (2011) GLP-1 playing the role of a gut regulatory compound. Acta Physiol 201:151-156. doi:10.1111/j.1748-1716.2010.02150.x
52. Hellström PM, Hein J, Bytzer P, Björnssön E, Kristensen J, Schambye H (2008) Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study. Aliment Pharmacol Ther 29:198-206. doi:10.1111/j.1365-2036.2008.03870.x
53. Herman J, Pokkunuri V, Braham L, Pimentel M (2010) Gender distribution in irritable bowel syndrome is proportional to the severity of constipation relative to diarrhea. Gend Med 7:240-246. doi:10.1016/j.genm.2010.06.007
54. Hirata T, Funatsu T, Keto Y, Nakata M, Sasamata M (2007) Pharmacological profile of ramosetron, a novel therapeutic agent for IBS. Inflammopharmacology 15:5-9. doi:0.1007/s10787-006-1537-1
55. Hochstrasser B, Angst J (1996) The Zurich Study: XXII. Epidemiology of gastrointestinal complaints and comorbidity with anxiety and depression. Eur Arch Psychiatry Clin Neurosci 246:261-272. doi:10.1007/BF02190278
56. Houghton LA, Cremonini F, Camilleri M, Busciglio I, Fell C, Cox V, Alpers DH, Dewit OE, Dukes GE, Gray E, Lea R, Zinsmeister AR, Whorwell PJ (2007) Effect of the NK3 receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans. Neurogastroenterol Motil 19:732-743. doi:10.1111/j.1365-2982.2007.00934.x
57. Houghton LA, Foster JM, Whorwell PJ (2000) Alosetron, a 5HT3- receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther 14:775-782. doi:10.1046/j.1365-2036. 2000.00762.x
58. Houghton LA, Lea R, Jackson N, Whorwell PJ (2002) The menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not healthy volunteers. Gut 50:471-474. doi:10.1136/gut.50.4.471
59. Ji Y, Murphy AZ, Traub RJ (2003) Estrogen modulates the visceromotor reflex and responses of spinal dorsal horn neurons to colorectal stimulation in the rat. J Neurosci 23:3908-3915
60. Kang JY (2005) Systematic review: the influence of geography and ethnicity in irritable bowel syndrome. Aliment Pharmacol Ther 21:663-76
61. Koloski NA, Talley NJ, Boyce PM (2001) Predictors of health care seeking for irritable bowel syndrome and nonulcer dyspepsia: a critical review of the literature on symptom and psychosocial factors. Am J Gastroenterol 96:1340-1349. doi:10.1111/j.1572-0241.2001.03789.x
62. Labus JS, Naliboff BN, Fallon J, Berman SM, Suyenobu B, Bueller JA, Mandelkern M, Mayer EA (2008) Sex differences in brain activity during aversive visceral stimulation and its expectation in patients with chronic abdominal pain: a network analysis. Neuroimage 41:1032-1043. doi:10.1016/j.neuroimage. 2008.03.009
63. Lacy BE, Chey WD (2009) Lubiprostone: chronic constipation and irritable bowel syndrome with constipation. Expert Opin Pharmacother 10:143-152. doi:10.1517/14656560802631319
64. Laessle RG, Tuschi RJ, Schweiger U, Pirke KM (1990) Mood changes and physical complaints during the normal menstrual cycle in healthy young women. Psychoneuroendocrinology 15:131-138. doi:10.1016/0306-4530(90)90021-Z
65. Layer P, Andresen V, Pehl C, Allescher H, Bischoff SC, Claßen M, Enck P, Frielling T, Haag S, Holtmann G, Karaus M, Kathemann S, Keller J, Kuhlbusch-Zicklam R, Kruis W, Langhorst J, Matthes H, Mönnikes H, Müller-Lissner S, Musial F, Otto B, Rosenberger C, Schemann M, van der Voort I, Dathe K, Preiß JC (2011) Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management. Z Gastroenterol 49:237-293. doi:10.1055/s-0029-1245976
66. Lee OY, Mayer EA, Schmulson M, Chang L, Naliboff B (2001) Gender related differences in IBS-symptoms. Am J Gastroenterol 96:2184-2193. doi:10.1111/j.1572-0241.2001.03961.x
67. Levy RL, Olden KW, Naliboff BD, Bradley LA, Francisconi C, Drossman DA, Creed F (2006) Psychosocial aspects of the functional gastrointestinal disorders. Gastroenterology 130:1447-1458. doi:10.1053/j.gastro.2005.11.057
68. Liu JP, Yang M, Liu Y, Wei ML, Grimsgaard S (2006) Herbal medicines for treatment of irritable bowel syndrome (Revie). Cochrane Database Syst Rev 1:1-119. doi:10.1002/14651858. CD004116.pub2
69. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC (2006) Functional bowel disorders. Gastroenterology 130:1480-1491. doi:10.1053/j.gastro.2005.11.061
70. Lunsford TN, Harris LA (2010) Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome. Int J Womens Health 2:361-74. doi:10.2147/IJWH.S4537
71. Lydiard RB, Fossey MD, Marsh W, Ballenger JC (1993) Prevalence of psychiatric disorders in patients with irritable bowel syndrome. Psychosomatics 34:229-234
72. Madisch A, Holtmann G, Plein K, Hotz J (2004) Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther 19:2741-279. doi:10.1111/j.1365-2036.2004.01859.x
73. Mangel AW, Chaturvedi P (2008) Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients. Digestion 78:180-186. doi:10.1159/000185719
74. Mangel AW, Bornstein JD, Hamm LR, Buda J, Wang J, Irish W, Urso D (2008) Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther 28:239-249. doi:10.1111/j.1365-2036.2008.03730. x
75. Mayer EA, Berman S, Chang L, Naliboff BD (2004) Sex-based differences in gastrointestinal pain. Eur J Pain 8:451-463. doi:10.1016/j.ejpain.2004.01.006
76. Mayer EA, Naliboff BD, Craig B (2006) Neuroimaging of the brain gut axis: from basic understanding to treatment of functional GI disorders. Gastroenterology 131:1925-1941. doi:10.1053/j.gastro.2006.10.026
77. McFarland LV, Dublin S (2008) Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 14:2650-2661. doi:10.3748/wjg.14.2650
78. Mertz HR (2003) Irritable bowel syndrome. N Engl J Med 349:2136-2146
79. Michael S, Kelber O, Hauschildt S, Spanel-Borowski K, Nieber K (2009) Inhibition of inflammation-induced alterations in rat small intestine by the herbal preparations STW 5 and STW 6. Phytomedicine 16:161-171. doi:10.1016/j.phymed.2008.10.011
80. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, Quigley EMM (2010) The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 59:325-332. doi:10.1136/gut.2008.167270
81. 4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 15:1655-1666. doi:10.1046/j.1365-2036.2001.01094.x
82. Myers B, Schulkin J, Greenwood-Van Meerveld B (2011) Sex steroids localized to the amygdala increase pain responses to visceral stimulation in rats. J Pain 12:486-494. doi:10.1016/j.pain.2010.10.007
83. Naliboff BD, Berman S, Chang L, Derbyshire SW, Suyenobu B, Vogt BA, Mandelkern M, Mayer EA (2003) Sex-related differences in IBS patients: central processing of visceral stimuli. Gastroenterology 124:1738-47. doi:10.1016/S0016-5085(03)00400-1
84. Ouyang A, Wrzos HF (2006) Contribution of gender to pathophysiology and clinical presentation of IBS: should management be different in women? Am J Gastroenterol 101:S602-S609. doi:10.1111/j.1572-0241.2006.00975.x
85. Park JH, Rhee PL, Kim HS, Lee JH, Kim YH, Kim JJ, Rhee JC (2006) Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. J Gastroenterol Hepatol 21:71-78. doi:10.1111/j.1440-1746.2005.04143.x
86. Payne S (2004) Sex, gender, and irritable bowel syndrome: making the connections. Gend Med 1:18-28. doi:10.1016/S1550-8579(04)80007-X
87. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP (2011) Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 364:22-32. doi:10.1056/NEJMoa1004409
88. Pitz M, Cheang M, Bernstein CN (2005) Defining the predictors of the placebo response in irritable bowel syndrome. Clin Gastroenterol Hepatol 3:237-247. doi:10.1016/S1542-3565 (04)00626-3
89. Poynard T, Regimbeau C, Benhamou Y (2001) Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 15:355-361. doi:10.1046/j.1365-2036.2001.00937.x
90. Quartero AO, Meiniche-Schmidt V, Muris J, Rubin G, de Wit N (2005) Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome (Review) Cochrane Database Syst Rev (2):CD003460. doi:10.1002/14651858.CD003460.pub2
91. Rybaczyk LA, Bashaw MJ, Pathak DR, Moody SM, Gilders RM, Holzschuh DL (2005) An overlooked connection: serotonergic mediation of estrogen-related physiology and pathology. BMC Womens Health 5:12. doi:10.1186/1472-6874-5-12
92. Saito YA, Schoenfeld P, Locke GR 3rd (2002) The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 97:1910-1915. doi:10.1111/j.1572-0241.2002.05913.x
93. Sainsbury A, Ford AC (2011) Treatment of irritable bowel syndrome. Therap Adv Gastroenterol 4:115-127. doi:10.1177/1756283X10387203
94. Schempp H, Weiser D, Kelber O, Elstner EF (2006) Radical scavenging and anti-inflammatory properties of STW 5 (Iberogast) and its components. Phytomedicine 13:36-44. doi:10.1016/j.phymed.2006.03.017
95. Shekhar C, Whorwell PJ (2009) Emerging drugs for irritable bowel syndrome. Expert Opin Emerging Drugs 14:673-685. doi:10.1517/14728210903222279
96. Shen YA, Nahas R (2009) Complementary and alternative medicine for treatment of irritable bowel syndrome. Can Fam Physician 55:143-148, PMCID:PMC2642499
97. Simrén M, Abrahamsson H, Svedlund J, Björnsson ES (2001) Quality of life in patients with irritable bowel syndrome seen in referral centers versus primary care: the impact of gender and predominant bowel pattern. Scand J Gastroenterol 36:545-552
98. Spiller RC (1999) Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials. Am J Med 107:91S-97S. doi:10.1016/S0002-9343(99) 00086-8
99. Spiller RC (2008) Review article: probiotics and prebiotics in irritable bowel syndrome. Aliment Pharmacol Ther 28:385-396. doi:10.1111/j.1365-2036.2008. 03750.x
100. Spiller RC (2011) Targeting the 5-HT3 receptor in the treatment of irritable bowel syndrome. Curr Opin Pharmacol 11:68-74. doi:10.1016/j.coph. 2011.02.005
101. Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, Jones R, Kumar D, Rubin G, Trudgill WP (2007) Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 56:1770-1798. doi:10.1136/gut.2007. 119446
102. Suares NC, Ford AC (2011) Diagnosis and treatment of irritable bowel syndrome. Discov Med 11:425-433
103. Tack J, Fried M, Houghton LA, Spicak J, Fisher G (2006) Systematic review: the efficacy of treatments for irritable bowel syndrome: a European perspective. Aliment Pharmacol Ther 24:183-205. doi:10.1111/j.1365-2036.2006. 02938.x
104. Talley NJ (2006) Irritable bowel syndrome. Intern Med J 36:724-728. doi:10.1111/j.1445-5994.2006.01217.x
105. Tillisch K, Mayer EA, Labus JS, Stain J, Chang L, Naliboff BD (2005) Sex specific alterations in autonomic function among patients with irritable bowel syndrome. Gut 54:1396-1401. doi:10.1136/gut.2004.058685
106. Toner BB (2005) Cognitive-behavioral treatment of irritable bowel syndrome. CNS Spectr 10:883-890
107. Toner BB, Akman D (2000) Gender role and irritable bowel syndrome: a literature review and hypothesis. Am J Gastroenterol 95:11-16. doi:10.1111/j.1572-0241.2000.01698.x
108. Westbrook JI, Talley NJ, Westbrook MT (2002) Gender differences in the symptoms and physical and mental well-being of dyspeptics: a population based study. Qual Life Res 11:283-291
109. Whitehead WE, Palsson O, Jones KR (2002) Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 122:1140-1156. doi:10.1053/gast.2002. 32392
110. Wittmann T, Paradowski L, Ducrotté P, Bueno L, Andro Delestrain MC (2010) Clinical trial: the efficacy of alverine citrate/simethicone combination on abdominal pain/discomfort in irritable bowel syndrome - a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 31:615-624. doi:10.1111/j.1365-2036.2009.04216.x
111. Wu JCY (2010) Complementary and alternative methods for the treatment of irritable bowel syndrome: facts or myths? Gastroenterol Motil 6:705-711, PMCID:PMC3033541
112. Yanagita T, Miyasato K, Sato J (1979) Dependence potential of loperamide studied in rhesus monkeys. NIDA Res Monogr 27:106-113. doi:10.1.1.152.5864
113. Zakko S, Barton G, Weber E, Dunger-Baldauf C, Rühl A (2011) Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK 333, in women with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 33:1311-1321. doi:10.1111/j.1365-2036.2011. 04656.x
114. http://www.clinicaltrials.gov
115. http://www.napopharma.com/products/crofelemerFS2.pdf
116. http://www.neurourogastro.typepad.com/blog/2011/05/rdx5791-a-first-in- class-minimally-systemic-nhe3-inhibitor-in-clinical-development-for-cic-and-ibs- c.html